drugset / Trial / NCT04189705

A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis

NCT04189705

Phase 3 Completed 392 enrolled Korea Otsuka Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multi-center, randomized, double-blind, active-controlled, non-inferiority, phase 3 study to evaluate the efficacy and safety of MCT-SR in patients with gastritis.

Timeline

Start
2019-12-30
Primary completion
2020-04-23
Completion
2020-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Rebamipide Small molecule 100 mg
Subject Rebamipide Small molecule 150 mg

Indications